General
Preferred name
Cirtuvivint
Synonyms
SM08502 ()
P&D ID
PD164710
CAS
2143917-62-6
Tags
available
drug candidate
Drug Status
investigational
Max Phase
1.0
Drug indication
Myelodysplastic syndrome
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research[1].
PRICE 357
DESCRIPTION Cirtuvivint (SM08502) is an orally bioavailable, pan-CLK/DYRK inhibitor , that was developed for anti-tumour activity. (GtoPdb)
DESCRIPTION Cirtuvivint (SM08502) is a potent, orally active CDC-like kinase (CLK) inhibitor useful for the study of arthritis. (TargetMol Bioactive Compound Library)
Cell lines
2
Organisms
0
Compound Sets
6
ChEMBL Drugs
CHEMBL4784318
DrugBank
DB17269
Guide to Pharmacology
12620
MedChem Express Bioactive Compound Library
HY-137435
Selleckchem Bioactive Compound Library
cirtuvivint
TargetMol Bioactive Compound Library
T39608
External IDs
10
Properties
(calculated by RDKit )
Molecular Weight
427.21
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
5
Aromatic Ring Count
4
cLogP
3.03
TPSA
79.18
Fraction CSP3
0.25
Chiral centers
0.0
Largest ring
6.0
QED
0.54
QED
0.54
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
CLK
CDK
Pathway
Cell Cycle/Checkpoint
Cell Cycle/DNA Damage
Source data